Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.7.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jul. 31, 2017
Jul. 31, 2016
Jul. 31, 2015
Revenues:      
Clinical laboratory services $ 77,407 $ 70,915 $ 63,414
Product revenues 29,192 30,337 31,690
Royalty and license fee income 1,205 1,521 2,495
Total revenues 107,804 102,773 97,599
Operating costs, expenses and legal settlements, net:      
Cost of clinical laboratory services 45,400 42,859 39,589
Cost of product revenues 14,078 14,331 15,183
Research and development 2,928 3,524 3,350
Selling, general, and administrative 44,010 43,586 41,069
Provision for uncollectible accounts receivable 2,775 2,336 2,284
Legal fee expense 1,679 6,384 8,788
Legal settlements, net   (57,250) (11,458)
Total costs, expenses and legal settlements, net 110,870 55,770 98,805
Operating (loss) income (3,066) 47,003 (1,206)
Other income (expense):      
Interest 384 (136) (245)
Other 125 122 95
Foreign exchange gain (loss) 135 (474) (936)
(Loss) income before income taxes (2,422) 46,515 (2,292)
(Provision) benefit for income taxes (82) (1,229) 7
Net (loss) income $ (2,504) $ 45,286 $ (2,285)
Net (loss) income per common share:      
Basic (in Dollars per share) $ (0.05) $ 0.98 $ (0.05)
Diluted (in Dollars per share) $ (0.05) $ 0.97 $ (0.05)
Weighted average common shares outstanding:      
Basic (in Shares) 46,350 46,153 45,355
Diluted (in Shares) 46,350 46,602 45,355